OxyNorm Capsules in Post-Operative Pain Study
Launched by MUNDIPHARMA (CHINA) PHARMACEUTICAL CO. LTD · Aug 29, 2012
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
To evaluate the efficacy and safety of oxycodone immediate-release capsules compared with morphine immediate-release tablets in hospitalized patients with moderate to severe pain following surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients of either sex aged 18 to 80 years inclusive.
- • 2. Patients who have given written informed consent to participate in the study.
- • 3. Able and willing to communicate with the investigator and his/her staff.
- • 4. Free of anesthesia as assessed through question and answer interaction with nurse at which time oral medication is indicated.
- • 5. Reporting "moderate" or "severe" pain (VAS ≥ 4) related to surgery and requesting analgesics for pain relief.
- Exclusion Criteria:
- • 1. Patients have developed tolerance to or dependence on narcotic analgesics and/or alcohol.
- • 2. Patients with ASA ≥ 3 .
- • 3. Have any concomitant medical condition that would be adversely affected by analgesics or confound the quantification of analgesia, or could affect the absorption, metabolism or excretion of the study drugs in any clinically significant fashion.
- • 4. Have known hypersensitivity to any of the study medications or related agents.
- • 5. Have taken analgesic medications within three hours (wash-out) prior to dosing.
- • 6. Have developed complications from the surgical procedure that would confound the study.
- • 7. Have a history of severe iatrogenic adverse experiences.
- • 8. Mothers nursing their infant during the 24 hours following study drug administration, or pregnant women.
- • 9. Patient with Nothing Per Os (NPO) as stated in patient's chart or physician's order.
- • 10. Surgery in patients with epidural anesthesia
- • 11. Patients with Severe impairment of liver at preoperative stage (ALT, AST ≥ 1.5 times upper limit) and abnormal renal function.
- • 12. Patients with medical history of recovering from abnormal surgery anesthesia.
- • 13. Patients with medical history of hypertension (Systolic blood pressure ≥ 180Hg, Diastolic blood pressure 110Hg).
- • 14. Patients with shock.
- • 15. Patients with COPD.
- • 16. According to investigator to determine, patients are in addition the inclusion criteria and exclusion criteria for any other reason than not suitable in this study.
About Mundipharma (China) Pharmaceutical Co. Ltd
Mundipharma (China) Pharmaceutical Co., Ltd. is a leading pharmaceutical company dedicated to improving patient outcomes through innovative therapies and comprehensive healthcare solutions. As a subsidiary of the global Mundipharma network, the company focuses on the development and commercialization of a diverse portfolio of products across various therapeutic areas, including pain management, respiratory diseases, and oncology. With a commitment to research and development, Mundipharma (China) collaborates with healthcare professionals and stakeholders to address unmet medical needs in the region, ensuring high standards of quality and efficacy in all its clinical trials and product offerings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
XinMin Wu, Prof.
Principal Investigator
Peking University 1st Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials